Associated Papers
Inflammatory Giant Cell Carcinoma of the Lung: Clinicopathologic, Immunohistochemical, and Next-generation Sequencing Study of 14 Cases.
Suster DI et al.
The American Journal of Surgical Pathology, 2024
Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition.
Bando H et al.
Cancer Science, 2024
38263580 (PubMed )
Supplement: CAS-115-1014-s001.docx
A cellular and spatial atlas of TP53 -associated tissue remodeling in lung adenocarcinoma.
Zhao W et al.
Biorxiv : the Preprint Server for Biology, 2024
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
Windon AL et al.
Journal of Gastrointestinal Oncology, 2018
A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
Chen D et al.
Oncotarget, 2015
Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
Bisht S et al.
Medical Oncology (northwood, London, England), 2014
Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A et al.
Critical Reviews in Oncology/hematology, 2013
Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.
Gajate P et al.
Clinical Colorectal Cancer, 2012
A multicenter study of the frequency and distribution of GJB2 and GJB6 mutations in a large North American cohort.
Putcha GV et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2007
Select a paper to view details